Press Release, 1st December 2017
HIV Ireland ‘welcomes’ availability of PrEP in Ireland
‘PrEP is a crucial HIV prevention medication that can significantly reduce new HIV infections, but it needs to be available to everyone, not just those people who can afford it’
The announcement by TEVA Pharmaceutical Company that it will be introducing Pre-Exposure Prophylaxis (PrEP) to Ireland from Monday 4th December has been welcomed by HIV Ireland. With Ireland facing the prospect that new HIV diagnoses will top 500 for the second year in a row, the introduction of PrEP could be a real gamechanger when it comes to the prevention of HIV transmission.
PrEP is a once daily medication that, in combination with safer-sex practices, has been proven to significantly reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, and has contributed to a 40% decrease in new HIV diagnoses in several clinics in London alone.
Niall Mulligan, Executive Director of HIV Ireland welcomed the news from TEVA as ‘a step in the right direction’ but warned that ‘even at a reduced cost of approximately €100 per month it remains out of reach for many people who would benefit from PrEP. We renew our call on the Government to make PrEP available to all people who need it, and not allow price to be a barrier’.
For further information, please contact:
70 Eccles Street
Mobile: 085 7457951
Tel: 01 8733799